Thrombin receptor antagonists

Details Thrombin receptor antagonists Thrombin receptor antagonists

2005-05-17

2005-05-17

Desai, Rita (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S152000, C546S284100, C544S224000

Reexamination Certificate

active

06894065

ABSTRACT:
Heterocyclic-substituted compounds of the formulaor a pharmaceutically acceptable salt thereof, are disclosed, wherein:Z is —(CH2)n—; wherein R10is absent; or wherein R3is absent;the single dotted line represents an optional double bond;the double dotted line represents an optional single bond;n is 0-2;Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group;B is —(CH2)n3—, wherein n3is 0-5, —CH2—O—, —CH2S—, —CH2—NR6—, —C(O)NR6—, —NR6C(O)—, optionally substituted alkenyl or optionally substituted alkynyl;X is —O— or —NR6— when the double dotted line represents a single bond, or X is H, —OH or —NHR20when the bond is absent;Y is ═O, ═S, (H, H), (H, OH) or (H, C1-C6alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is ═O, ═NOR17, (H, H), (H, OH), (H, SH), (H, C1-C6alkoxy) or (H, substituted-amino);R22and R23are independently —OH, —OC(O)R30, OC(O)NR30R31, or optionally substituted alkyl, alkenyl, alkynyl, heterocycloalkyl, aryl, cycloalkyl, cycloalkenyl, carbonyl, amino, alkoxy, alkenyloxy, alkynyloxy, heterocycloalkyloxy, cycloalkyloxy, or cycloalkenyloxy; or R22and R10, or R23and R11, can form a carbocyclic or heterocyclic ring;and the remaining variables are as described in the specification.Also disclosed are pharmaceutical compositions containing said compounds and their use as thrombin receptor antagonists and binders to cannabinoid receptors.

REFERENCES:
patent: 6063847 (2000-05-01), Chacklamannil et al.
patent: 6326380 (2001-12-01), Chackalamannil et al.
patent: 6392059 (2002-05-01), Terashima et al.
patent: 9403479 (1994-02-01), None
patent: 9926943 (1999-06-01), None
Bernatowicz et al,J. Med. Chem.,39 (1996), p. 4879-4887.
Chackalamannil et al,J. Am. Chem. Soc.,118 (1996), p. 9812-9813.
Pertwee,Curr. Med. Chem.,6 (1999), p. 635-664.
Mordini et al,J. Org. Chem.,59 (1994), p. 4784-4790.
McGinnis et al,J. Chem. Soc.,(1941), p. 404-408.
Wang et al,Tet. Lett.,41 (2000), p. 4335-4338.
Natarajan et al,Int. J. Peptide Protein Res.,45 (1995), p. 145-151.
Lowrey et al,J. Biol. Chem.,193 (1951), 265-275.
Ahn et al,Mol. Pharmacol.,51 (1997), p. 350-356.
Bednar et al,Thromb. Res.,77 (1995), p. 453-463..
Even-Ram et al,Nature Med.,4, (8) (1988), p. 909-914.
Showalter et al,J. Pharmacol. Exp. Ther.,278 (3) (1996), p. 989-999.

Affiliated with

Also associated with

Rating

Thrombin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thrombin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thrombin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3408406